Biomerica Inc reports Q2 EPS (5c), one est. (6c)
Reports Q2 net sales $1.59M, one est. $1.42M. "We are excited about progress we're making in moving toward completion of the clinical trials for our InFoods(R) IBS product and H. pylori diagnostic product. The addition of Houston Methodist should significantly accelerate the completion of the current endpoint trial and play a significant role in the final trial needed for FDA clearance. We are also in late stage discussions to add additional large medical centers who are excited to participate in the InFoods trials," said Zack Irani, CEO of Biomerica. "We are expecting calendar 2020 to be a breakout year for Biomerica as our shareholders begin to reap the benefits of years of research, development and clinical trials."